布地奈德福莫特罗对轻中度支气管哮喘急性发作患者肺通气功能及预后的影响  

Effects of Budesonide and Formoterol on Pulmonary Ventilation Function and Prognosis in Patients with Acute Exacerbation of Mild to Moderate Bronchial Asthma

作　　者：张巧丽[1] 邓在春[1] 孙士芳[1] 胡征[2] 翁磊 马红映[1] 丁群力[1] 

机构地区：[1]宁波大学医学院附属医院呼吸科,浙江宁波315020 [2]慈溪市人民医院呼吸科,浙江慈溪315300 [3]宁波市第九医院呼吸科,浙江宁波315000

出　　处：《中国药房》2017年第36期5076-5079,共4页China Pharmacy

基　　金：浙江省自然科学基金资助项目(No.LY15H010004);宁波市第二批科技项目(No.2014A610279)

摘　　要：目的:探讨布地奈德福莫特罗对轻中度支气管哮喘急性发作患者肺通气功能及预后的影响。方法:89例轻中度支气管哮喘急性发作患者随机分为研究组(45例)和对照组(44例)。研究组患者给予布地奈德福莫特罗干粉吸入剂1吸,每6 h 1次,每次吸药后均反复漱口5次,每日不超过6吸+孟鲁司特片10 mg,口服,每晚1次。对照组患者给予强的松片25 mg,d_(1-5),早餐后口服,每日1次+茶碱缓释胶囊0.2 g,口服,每日2次+孟鲁司特片10 mg,口服,每晚1次。两组疗程均为5 d。观察两组患者治疗前后急性哮喘生活质量问卷(AQLQ)评分、第1秒用力呼气量(FEV1)、呼气峰流速占预计值百分比(PEF%pred)、血氧饱和度(SpO_2),并记录不良反应发生情况。结果:治疗前,两组患者急性AQLQ评分、FEV1、PEF%pred、SpO_2比较,差异均无统计学意义(P>0.05)。治疗后,两组患者急性AQLQ评分、FEV1、PEF%pred、SpO_2均显著高于同组治疗前,差异均有统计学意义(P<0.05);但两组间比较差异无统计学意义(P>0.05)。研究组患者不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论:布地奈德福莫特罗可显著改善轻中度支气管哮喘急性发作患者的肺通气功能及预后,且安全性较好。OBJECTIVE： To observe therapeutic efficacy and safety of budesonide and formoterol in the treatment of acute ex- acerbation of mild to moderate asthma. METHODS ： A total of 89 patients with acute exacerbation of mild to moderate asthma were randomized divded into study group （45 cases） and control group （44 cases）. Study group was given Budesonide and formoterol dry powder inhalation, one inhalation, q6 h, gargling 5 times after inhalation, 6 inhalation per day at most＋Montelukast tablet 10 mg orally, once a day. Control group received Prednisone tablet 25 mg orally after breakfast, once a day, d1-5＋Theophylline sus- tained-release capsule 0.2 g, twice a day＋Montelukast tablet 10 mg, once a day in the evening. Both groups were treated for 5 d. Acute AQLQ score, FEV1, PEF%pred and SpO2 were observed in 2 groups before and after treatment, and the occurrence of ADR was recorded. RESULTS： Before treatment, there was no statistical significance in acute AQLQ score, FEV1, PEF%pred or SpO2 between 2 groups（P〉0.05）. After treatment, acute AQLQ score, FEV1, PEF%pred and SpO2 of 2 groups were significantly higher than before treatment, with statistical significance （P〈0.05）,but there was no statistical significance between 2 groups （P〉 0.05）. There was statistical significance in the incidence of ADR between 2 group（P〈0.05）. CONCLUSIONS： Budesonide and for- moterol can improve pulmonary ventilation function and prognosis in patients with acute exacerbation of mild to moderate asthma with good safety.

关 键 词：布地奈德福莫特罗 支气管哮喘 急性发作 肺通气功能 预后 

分 类 号：R562.2[医药卫生—呼吸系统]